Cargando…
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.
Octreotide, a somatostatin analogue, has been shown to inhibit the growth of gastrointestinal cancers in vitro and in vivo. To assess the anti-tumour effect of octreotide, we performed a randomised trial comparing octreotide with best supportive care in advanced gastrointestinal cancer patients refr...
Autores principales: | Cascinu, S., Del Ferro, E., Catalano, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033463/ https://www.ncbi.nlm.nih.gov/pubmed/7819058 |
Ejemplares similares
-
Octreotide as an adjunct in the management of arterial gastrointestinal bleeding: Should it be considered in refractory cases of obscure origin?
por: Martins, Noel B., et al.
Publicado: (2017) -
The Clinical Challenge of Refractory Octreotide-Induced Thrombocytopenia in Active Gastrointestinal Bleeding: A Case Report
por: Abu-Abaa, Mohammad, et al.
Publicado: (2023) -
Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.
por: Helle, S. I., et al.
Publicado: (1998) -
Refractory gastric ulcer bleeding responsive to long-term octreotide
por: Iqbal, Humzah, et al.
Publicado: (2023) -
Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
por: Patel, Ankoor H, et al.
Publicado: (2023)